The quadrivalent recombinant influenza vaccine (RIV4) demonstrated non-inferior immune responses in children and adolescents aged 9-17 years compared with adults aged 18-49 years, with the safety ...

Everon Healthcare is a distinguished Chinese company focused on the research, development and industrialization of recombinant triple-helical collagen.

First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC ...

Recombinant quadrivalent influenza vaccine (RIV4) and standard egg-based quadrivalent inactivated IV (IIV4) show comparable effectiveness in reducing influenza-related hospitalization among older ...

Credit: ImmunityBio. Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...